Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
AI Bubble Risks Make Dividend Stocks Attractive Again
01:03pm, Saturday, 18'th Jul 2026
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates qualit
Aqemia and Sanofi Expand Their Research Collaboration
06:30am, Friday, 17'th Jul 2026
PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion
3 High-Yield Dividend Stocks to Buy and Hold
01:00am, Friday, 17'th Jul 2026
All three can be bought on the dip.
Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
US FDA approves Sanofi's wearable injector form of blood cancer drug
08:22am, Friday, 10'th Jul 2026
The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector,
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
06:00am, Wednesday, 08'th Jul 2026
The European Commission said on Wednesday it would seek feedback on commitments offered by French pharmaceutical company Sanofi to address concerns that it may have breached competition �
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
10:26am, Wednesday, 01'st Jul 2026
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Press Release: Availability of the aide-mémoire for Q2 2026 results
01:30am, Wednesday, 01'st Jul 2026
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
03:04pm, Tuesday, 30'th Jun 2026
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive d
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
05:46am, Friday, 26'th Jun 2026
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Is AbbVie a Buy After Its Purchase of Apogee?
09:53am, Thursday, 25'th Jun 2026
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity
07:18am, Thursday, 25'th Jun 2026
Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1
Press Release: Sanofi Foundation opens new chapter centered on future generations
02:00am, Thursday, 25'th Jun 2026
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
12:26pm, Tuesday, 23'rd Jun 2026
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
